Related Experiment Videos
Rapid drop in serum testosterone after bilateral subcapsular orchiectomy.
1Department of Surgery, Presbyterian Hospital, Whittier, California.
Journal of Surgical Oncology
|January 1, 1992
Summary
Bilateral subcapsular orchiectomy rapidly reduces testosterone levels in metastatic prostate cancer patients, offering a cost-effective alternative to hormone therapies. This surgical option achieves castration levels within hours, unlike slower-acting drug treatments.
Area of Science:
- Urology
- Oncology
- Endocrinology
Background:
- Metastatic prostatic carcinoma requires effective testosterone suppression.
- Hormonal therapies like luteinizing hormone-releasing hormone (LH-RH) agonists are common treatments.
- The speed and cost-effectiveness of testosterone suppression methods are critical considerations.
Purpose of the Study:
- To evaluate the speed of testosterone level reduction following bilateral subcapsular orchiectomy.
- To compare the cost-effectiveness of orchiectomy versus LH-RH agonists for managing metastatic prostate cancer.
Main Methods:
- Bilateral subcapsular orchiectomy performed in six patients with metastatic prostatic carcinoma.
- Serial serum testosterone level determination up to 24 hours post-procedure.
Main Results:
- Castrate levels of serum testosterone were achieved approximately 2.5 hours after orchiectomy.
- This represents a significantly faster reduction compared to LH-RH agonists (14-21 days).
- The 36-month cost for orchiectomy was $2,042.00, versus $12,780.00 for LH-RH agonists.
Conclusions:
- Bilateral subcapsular orchiectomy provides rapid and cost-effective testosterone suppression for metastatic prostate cancer.
- Urologists should consider orchiectomy as a primary management strategy over LH-RH agonists due to its speed and economic benefits.
- The efficacy of LH-RH agonists may be limited to one year, further supporting orchiectomy's long-term value.